Screener
Syndax Pharmaceuticals SNDX Business Segments — Royalty Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RoyaltyExpense.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 99,066 | 103,799 |
| Loss from operations | (34,202) | (83,757) |
| Other (expense) income, net: | ||
| Royalty interest expense | (11,846) | (8,049) |
| Other interest expense | — | (2) |
| Interest income | 3,561 | 7,183 |
| Other expense | (186) | (221) |
| Total other (expense) income, net | (8,471) | (1,089) |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's business segments — royalty expense?
- Syndax Pharmaceuticals (SNDX) reported business segments — royalty expense of $11.85M in Q1 2026.
- How has Syndax Pharmaceuticals's business segments — royalty expense changed year-over-year?
- Syndax Pharmaceuticals's business segments — royalty expense increased by 47.2% year-over-year, from $8.05M to $11.85M.
- What does business segments — royalty expense mean?
- This represents the payments made to third parties, such as academic institutions or licensing partners, based on the commercial sales of the company's products. It reflects the cost of accessing intellectual property or proprietary technology essential for the company's therapeutic candidates. High royalty obligations can significantly impact the net profitability of a commercialized product.
Ask your AI about Syndax Pharmaceuticals's business segments — royalty expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude